The FDA Rejects MDMA-Assisted Therapy

In this episode, Dr. Dave Rabin discusses the impact of the FDA's decision, the potential delays in accessing this crucial treatment, and the unethical behavior of certain organizations influencing the FDA. Dr. Rabin is joined by Jon Lubecky, a retired army sergeant and Veteran who took part in MAPS MDMA therapy trials, as he discusses the implications of this rejection and emphasizes the need for ongoing advocacy and hope for eventual approval. The episode also addresses the unethical behavior of Symposia, an organization accused of falsifying information to the FDA to obstruct MDMA therapy approval. Additionally, former Symposia member David Nichols reveals serious ethical violations within the organization, raising questions about their motives and funding. Through these discussions, the episode highlights the critical need for transparency, ethical practices, and continued efforts to ensure access to psychedelic treatments for those in need.Rachel Nuwer’s Scientific American Article: https://www.scientificamerican.com/article/fdas-rejection-of-mdma-psychotherapy-for-trauma-draws-criticism-from/Jon Lubecky’s Conversation with David Nickles on Breaking Points: https://www.youtube.com/watch?v=lttFB0c0cAo Web: https://psychedelic.support/ Twitter: https://twitter.com/DrDavidRabin Instagram: https://www.instagram.com/drdavidrabin Web: https://www.drdave.io/ Food and Drug Administration5630 Fishers LaneRm. 1061Rockville, MD 20852Docket No. FDA-2024-N-193